87121-89-9

Basic information

• Product Name: ETHYL 3-OXO CYCLOBUATNE CARBOXYLATE
• Synonyms: ETHYL 3-OXO CYCLOBUATNE CARBOXYLATE;ethyl 3-oxocyclobutanecarboxylate;3-Oxo-cyclobutanecarboxylic acid ethyl ester;Cyclobutanecarboxylic acid, 3-oxo-, ethyl ester;Ethyl oxetane-3-carboxylate;Methyl 3,3,3-trifluoro-2-iminopropanoate;Ethyl 3-oxocyclobuantecarboxylate;ethyl 3-oxocyclobutane-1-carboxylate
• CAS NO: 87121-89-9
• Molecular Formula: C₇H₁₀O₃
• Molecular Weight: 142.16
• Mol File: 87121-89-9.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 206.9 °C at 760 mmHg
• Flash Point: 82.3 °C
• Appearance: /
• Density: 1.169 g/cm³
• Vapor Pressure: 0.231mmHg at 25°C
• Refractive Index: 1.473
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• CAS DataBase Reference: ETHYL 3-OXO CYCLOBUATNE CARBOXYLATE(CAS DataBase Reference)
• NIST Chemistry Reference: ETHYL 3-OXO CYCLOBUATNE CARBOXYLATE(87121-89-9)
• EPA Substance Registry System: ETHYL 3-OXO CYCLOBUATNE CARBOXYLATE(87121-89-9)

Safety Data

• Hazardous Substances Data: 87121-89-9(Hazardous Substances Data)

Usage

Uses

Ethyl 3-oxocyclobutanecarboxylate is used as pharmaceutical intermediate.

InChI:InChI=1/C7H10O3/c1-2-10-7(9)5-3-6(8)4-5/h5H,2-4H2,1H3

Upstream product

• 64-17-5 ethanol 
• 23761-23-1 3-oxocyclobutanecarboxylic acid 
• 140-88-5 ethyl acrylate 
• 130233-77-1 3-oxocyclobutane-1-carbonyl chloride 
• 122-51-0 orthoformic acid triethyl ester 
• 4958-02-5 3-(benzyloxy)cyclobutane-1-carboxylic acid 
• 4934-97-8 diisoamyl 3-benzyloxycyclobutane-1,1-dicarboxylate 
• 106596-81-0 3-benzyloxy-cyclobutanecarboxylic acid ethyl ester 
• 78-39-7 Triethyl orthoacetate 
• 17205-02-6 ethyl trans-3-hydroxycyclobutanecarboxylate 

Downstream Products

• 1611444-74-6 ethyl 3-[(2-bromo-5-chlorophenyl)methylene]cyclobutanecarboxylate 
• 5204-92-2 ethyl 5-oxotetrahydro-3-furancarboxylate 
• 1332706-65-6 3-{[5-(biphenyl-4-yl)-6-chloro-1H-benzimidazol-2yl]oxy}cyclobutanecarboxylic acid 
• 1332706-96-3 ethyl 3-{[5-(biphenyl-4-yl)-6-chloro-1-{[2-(trimethylsilyl)ethoxy]-methyl}-1H-benzimidazol-2-yl]oxy}cyclobutanecarboxylate 
• 1332706-79-2 3-{[5-(biphenyl-4-yl)-4,6-difluoro-1H-benzimidazol-2-yl]oxy}cyclobutanecarboxylic acid 

Relevant articles and documents

COMPOUND AS ACC INHIBITOR AND USE THEREOF

Disclosed are a class of compounds which are inhibitors of acetyl-CoA carboxylase (ACC) and the use thereof. In particular, provided are compounds as shown in formula I or isomers, pharmaceutically acceptable salts, solvates, crystals or prodrugs thereof, and methods for preparing the same, and pharmaceutical compositions comprising the compounds and the use of the compounds or compositions for treating and/or preventing diseases associated with ACC expression, such as fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases. The compound has a good inhibitory activity against ACC and shows good promise to be a therapeutic drug for fibrotic diseases, metabolic diseases, cancers or tissue hyperplasia diseases.

Copper-Catalyzed Coupling Reactions of Cyclobutanone Oxime Esters with Sulfur Nucleophiles at Room Temperature

A copper-catalyzed iminyl radical-mediated C-C bond cleavage/cross-coupling tandem reaction of cyclobutanone oxime esters with aryl thiols in the presence of 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) at room temperature was developed, and aryl cyanopropyl sulfides were smoothly synthesized in 20-88% yields. By altering the copper reagent and the molar ratio of cyclobutanone oxime ester/aryl thiol/DBU, substitutional product N-arylthio cyclobutanone imines were selectively generated in 50-91% yields. Using this protocol, C-S bond and N-S bond formations using aryl thiols as sulfur sources were realized under very mild conditions without the use of photocatalysis and electrocatalysis techniques.

ISOXAZOLE DERIVATIVES FOR USE IN THE TREATMENT OF PULMONARY DISEASES AND DISORDERS

The present disclosure features disclosed method of treating disorders such as COPD, bronchitis and/or asthma using disclosed compounds, optionally together with one or more additional active agents. Contemplated methods include administrating orally or by inhalation to a patient one or more disclosed compounds.